Mangoceuticals Stock Rises After Successful Launch of TRT Program
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 20 2026
0mins
Should l Buy MGRX?
Source: Benzinga
- Significant Sales Growth: Since its launch in mid-December, Mangoceuticals' injectable Testosterone Replacement Therapy (TRT) program has seen a 336% month-over-month sales increase, indicating strong market demand and solidifying the company's position in men's hormone health.
- Reduced Customer Acquisition Costs: The company reported a 54% decrease in customer acquisition costs during the same period, demonstrating the effectiveness of its $99 subscription model, which enhances overall profitability and market competitiveness.
- Clear Strategic Focus: CEO Jacob Cohen emphasized that initial customer demand and sales acceleration validate the strategic value of the company's approach to men's hormone health, with injectable and oral formulations expected to drive future growth.
- Strong Stock Performance: As of now, Mangoceuticals shares have surged 56.16% to 56 cents, reflecting investor confidence in the company's new therapy and optimism about its market prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MGRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MGRX
About MGRX
Mangoceuticals, Inc. is focused on developing men’s and women’s health and wellness products and services via a secure telemedicine platform. The Company connects consumers to licensed healthcare professionals through its Website at www.MangoRX.com, for the provision of care via telehealth on its customer portal. It has developed and is commercially marketing a brand of erectile dysfunction (ED) products under the brand name Mango, a brand of hair-loss products under the brand name Grow, a brand of hormone balance and therapy products under the name Mojo, and a brand of weight-loss products under the brand name Slim. The Mango ED product includes the three ingredients: Either Sildenafil (the active ingredient in Viagra) or Tadalafil (the active ingredient in Cialis), and Oxytocin. Mango GROW includes four ingredients: Minoxidil (the active ingredient in Rogaine) and Finasteride (the active ingredient in Propecia), Vitamin D3 and Biotin, which are available as dietary supplements.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Mangoceuticals Files for Global Patent Protection on Antiviral Additive
- Global Patent Filing: Mangoceuticals filed a PCT international application on February 26, 2026, to secure global patent protection for its antiviral animal feed and drinking water additive technology MGX-0024, demonstrating the company's proactive approach in innovative health solutions.
- Clinical Trial Results: MGX-0024 achieved zero respiratory-related mortality across 29,000 birds in commercial field trials and showed statistically significant prophylactic benefits against highly pathogenic H5N1 in the ICAR-NIHSAD controlled challenge study, further solidifying its market competitiveness.
- Intellectual Property Expansion: The PCT application enables the company to pursue patent protection in over 150 countries through a streamlined process, indicating its strategic intent in global markets, particularly the commercialization potential in key markets like India.
- Current Technology Protection: MGX-0024 is protected in the U.S. under Patent No. 11,517,523, with corresponding national patents granted or pending in the EU, Canada, China, India, Australia, and Japan, ensuring comprehensive global coverage of its technology.
See More
Mangoceuticals Stock Surges 42.12% Amid TRT Sales Growth
- TRT Sales Surge: Since its mid-December launch, Mangoceuticals' injectable testosterone replacement therapy (TRT) sales have skyrocketed by 336% month-over-month, while customer acquisition costs have decreased by 54%, indicating strong market demand and effective cost management.
- Significant Market Potential: The company anticipates that TRT will be the primary growth driver as MangoRx expands both injectable and oral options, including the PRIME capsule powered by Kyzatrex, further enhancing its market share.
- Telehealth Platform Advantage: CEO Jacob Cohen highlighted that early demand underscores the value of the firm's telehealth-first approach to men's hormone care, aiming to improve marketing efficiency to meet the growing TRT market demand.
- Strong Stock Performance: As of Friday, Mangoceuticals shares surged 42.12% to $0.51, nearing its 52-week low of $0.34, reflecting investor optimism about the company's future growth potential.
See More
U.S. Stocks Rise, Nasdaq Gains Over 200 Points
- Nasdaq Performance: The Nasdaq Composite rose over 200 points on Friday, closing at 22,917.24, indicating strong demand for tech stocks and potentially reflecting investor optimism about future economic recovery.
- PPL Corporation Earnings: PPL Corporation reported mixed Q4 fiscal 2025 results with operating revenue of $2.27 billion, falling short of the $2.42 billion consensus estimate, although adjusted EPS of 41 cents met analyst expectations, highlighting challenges in revenue growth.
- Dividend Increase: PPL raised its quarterly dividend by 4.6% to 28.50 cents per share, demonstrating confidence in future cash flows and a commitment to shareholder returns amidst fluctuating earnings.
- Market Dynamics: On Friday, communication services stocks gained 2.3%, while healthcare stocks fell by 0.7%, indicating performance disparities across sectors that may influence investors' asset allocation strategies.
See More
U.S. Stocks Rise in Morning Trade Amid Slowing Economic Growth
- Market Performance: U.S. stocks rose in morning trading on Friday, with the Dow Jones gaining over 100 points, up 0.24% to 49,516.12, indicating a moderate optimistic sentiment in the market.
- Economic Slowdown: The U.S. economy grew at an annualized rate of 1.4% in Q4, the lowest since Q1 2025 and significantly below the market estimate of 3%, which may impact investor confidence moving forward.
- Sector Performance Divergence: Communication services shares rose by 1.7% on Friday, while energy stocks fell by 0.4%, reflecting varied market reactions across sectors that could influence capital flows.
- Commodity Market Dynamics: Oil prices dipped 0.1% to $66.42, while gold increased by 1% to $5,045.10, indicating that investors are seeking safe-haven assets amid economic uncertainty.
See More
Mangoceuticals Stock Rises After Successful Launch of TRT Program
- Significant Sales Growth: Since its launch in mid-December, Mangoceuticals' injectable Testosterone Replacement Therapy (TRT) program has seen a 336% month-over-month sales increase, indicating strong market demand and solidifying the company's position in men's hormone health.
- Reduced Customer Acquisition Costs: The company reported a 54% decrease in customer acquisition costs during the same period, demonstrating the effectiveness of its $99 subscription model, which enhances overall profitability and market competitiveness.
- Clear Strategic Focus: CEO Jacob Cohen emphasized that initial customer demand and sales acceleration validate the strategic value of the company's approach to men's hormone health, with injectable and oral formulations expected to drive future growth.
- Strong Stock Performance: As of now, Mangoceuticals shares have surged 56.16% to 56 cents, reflecting investor confidence in the company's new therapy and optimism about its market prospects.
See More
Comfort Systems Reports Strong Earnings Beat
- Earnings Beat: Comfort Systems reported earnings of $9.37 per share, surpassing the analyst consensus estimate of $6.75, indicating a significant improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $2.646 billion, exceeding the analyst consensus estimate of $2.337 billion, reflecting strong market demand and driving overall performance.
- Positive Stock Reaction: Comfort Systems shares jumped 4.6% to $1,436.25 in pre-market trading, indicating a favorable market response to the earnings report, which may attract more investor interest.
- Optimistic Market Outlook: The strong earnings data not only enhances the company's short-term stock price but also lays the groundwork for future growth, increasing market attractiveness for long-term investments in Comfort Systems.
See More
Mangoceuticals Files for Global Patent Protection on Antiviral Additive
- Global Patent Filing: Mangoceuticals filed a PCT international application on February 26, 2026, to secure global patent protection for its antiviral animal feed and drinking water additive technology MGX-0024, demonstrating the company's proactive approach in innovative health solutions.
- Clinical Trial Results: MGX-0024 achieved zero respiratory-related mortality across 29,000 birds in commercial field trials and showed statistically significant prophylactic benefits against highly pathogenic H5N1 in the ICAR-NIHSAD controlled challenge study, further solidifying its market competitiveness.
- Intellectual Property Expansion: The PCT application enables the company to pursue patent protection in over 150 countries through a streamlined process, indicating its strategic intent in global markets, particularly the commercialization potential in key markets like India.
- Current Technology Protection: MGX-0024 is protected in the U.S. under Patent No. 11,517,523, with corresponding national patents granted or pending in the EU, Canada, China, India, Australia, and Japan, ensuring comprehensive global coverage of its technology.
See More
Mangoceuticals Stock Surges 42.12% Amid TRT Sales Growth
- TRT Sales Surge: Since its mid-December launch, Mangoceuticals' injectable testosterone replacement therapy (TRT) sales have skyrocketed by 336% month-over-month, while customer acquisition costs have decreased by 54%, indicating strong market demand and effective cost management.
- Significant Market Potential: The company anticipates that TRT will be the primary growth driver as MangoRx expands both injectable and oral options, including the PRIME capsule powered by Kyzatrex, further enhancing its market share.
- Telehealth Platform Advantage: CEO Jacob Cohen highlighted that early demand underscores the value of the firm's telehealth-first approach to men's hormone care, aiming to improve marketing efficiency to meet the growing TRT market demand.
- Strong Stock Performance: As of Friday, Mangoceuticals shares surged 42.12% to $0.51, nearing its 52-week low of $0.34, reflecting investor optimism about the company's future growth potential.
See More
U.S. Stocks Rise, Nasdaq Gains Over 200 Points
- Nasdaq Performance: The Nasdaq Composite rose over 200 points on Friday, closing at 22,917.24, indicating strong demand for tech stocks and potentially reflecting investor optimism about future economic recovery.
- PPL Corporation Earnings: PPL Corporation reported mixed Q4 fiscal 2025 results with operating revenue of $2.27 billion, falling short of the $2.42 billion consensus estimate, although adjusted EPS of 41 cents met analyst expectations, highlighting challenges in revenue growth.
- Dividend Increase: PPL raised its quarterly dividend by 4.6% to 28.50 cents per share, demonstrating confidence in future cash flows and a commitment to shareholder returns amidst fluctuating earnings.
- Market Dynamics: On Friday, communication services stocks gained 2.3%, while healthcare stocks fell by 0.7%, indicating performance disparities across sectors that may influence investors' asset allocation strategies.
See More
U.S. Stocks Rise in Morning Trade Amid Slowing Economic Growth
- Market Performance: U.S. stocks rose in morning trading on Friday, with the Dow Jones gaining over 100 points, up 0.24% to 49,516.12, indicating a moderate optimistic sentiment in the market.
- Economic Slowdown: The U.S. economy grew at an annualized rate of 1.4% in Q4, the lowest since Q1 2025 and significantly below the market estimate of 3%, which may impact investor confidence moving forward.
- Sector Performance Divergence: Communication services shares rose by 1.7% on Friday, while energy stocks fell by 0.4%, reflecting varied market reactions across sectors that could influence capital flows.
- Commodity Market Dynamics: Oil prices dipped 0.1% to $66.42, while gold increased by 1% to $5,045.10, indicating that investors are seeking safe-haven assets amid economic uncertainty.
See More
Mangoceuticals Stock Rises After Successful Launch of TRT Program
- Significant Sales Growth: Since its launch in mid-December, Mangoceuticals' injectable Testosterone Replacement Therapy (TRT) program has seen a 336% month-over-month sales increase, indicating strong market demand and solidifying the company's position in men's hormone health.
- Reduced Customer Acquisition Costs: The company reported a 54% decrease in customer acquisition costs during the same period, demonstrating the effectiveness of its $99 subscription model, which enhances overall profitability and market competitiveness.
- Clear Strategic Focus: CEO Jacob Cohen emphasized that initial customer demand and sales acceleration validate the strategic value of the company's approach to men's hormone health, with injectable and oral formulations expected to drive future growth.
- Strong Stock Performance: As of now, Mangoceuticals shares have surged 56.16% to 56 cents, reflecting investor confidence in the company's new therapy and optimism about its market prospects.
See More
Comfort Systems Reports Strong Earnings Beat
- Earnings Beat: Comfort Systems reported earnings of $9.37 per share, surpassing the analyst consensus estimate of $6.75, indicating a significant improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $2.646 billion, exceeding the analyst consensus estimate of $2.337 billion, reflecting strong market demand and driving overall performance.
- Positive Stock Reaction: Comfort Systems shares jumped 4.6% to $1,436.25 in pre-market trading, indicating a favorable market response to the earnings report, which may attract more investor interest.
- Optimistic Market Outlook: The strong earnings data not only enhances the company's short-term stock price but also lays the groundwork for future growth, increasing market attractiveness for long-term investments in Comfort Systems.
See More
